On the stock market since 2017, it operates in the world of health and science. It has 44 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $8.0M against $0 in annual sales.
The stock sits at $0.72. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, BYSI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BYSI is a high-risk stock — not yet profitable, and its future rides on its product catching on.